The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
The Trump administration has quietly pulled the plug on a Medicare pilot program that would have expanded access to GLP-1 weight loss medications for seniors. If you're on Medicare and counting on that coverage, here's what you need to know — and what your options actually are.
South Korea's Ministry of Food and Drug Safety has officially designated Wegovy and Mounjaro as drugs with abuse concerns. This doesn't mean these medications are dangerous or being banned — but it does signal something worth understanding if you're on GLP-1 therapy.
Amazon has entered the GLP-1 medication space, promising fast and convenient access to weight loss drugs like semaglutide and tirzepatide. For people already navigating this therapy—or considering it—the news raises real questions. Here's an honest look at what this program means for patients.
Injectable GLP-1 medications have dominated the weight loss and diabetes space, but oral options are gaining serious ground. New developments in drug delivery technology are pushing the boundaries of what's possible in pill form. Here's what you need to know as a patient.
7 essential supplements to prevent nutrient loss on GLP-1 drugs.
GLP-1 safety for seniors plus Medicare 2026 coverage rules.
Save 22 to 37% on GLP-1s by paying with HSA or FSA dollars.
Saxenda vs Wegovy compared on results, cost, and dosing.
.avif)
%20(1).avif)
%20(1).avif)
.avif)